ABVX
Abivax SA
NASDAQ · Healthcare · Biotechnology · FR
$87.49
−0.73%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 5760.82x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 18.58x
- Price / sales
- —
- Price / cash flow
- -55.21x
Enterprise value
- Enterprise value
- $7.2B
- EV / sales
- —
- EV / EBITDA
- -16.88x
- EV / EBIT
- -22.55x
- Market cap
- $7.6B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026